Holen Sie sich die Stockscreener-App
1.47
2.80%
0.04
Handel nachbörslich:
1.45
-0.02
-1.36%
Schlusskurs vom Vortag:
$1.43
Offen:
$1.46
24-Stunden-Volumen:
222.87K
Relative Volume:
0.39
Marktkapitalisierung:
$90.55M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-0.8212
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
-4.55%
1M Leistung:
+0.68%
6M Leistung:
-52.35%
1J Leistung:
-74.35%
1-Tages-Spanne:
$1.45
$1.54
1-Wochen-Bereich:
$1.40
$1.5876
52-Wochen-Spanne:
$1.02
$7.89
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.47 | 90.55M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80 - Defense World
Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell - Defense World
Bank of America Corp DE Has $456,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Wellington Management Group LLP Boosts Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
ProShare Advisors LLC Makes New $40,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BNP Paribas Financial Markets Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - Barchart.com
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Stifel Financial Corp Acquires 10,567 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Barclays PLC - Defense World
H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating - Investing.com Nigeria
Equities Analysts Set Expectations for TCRX Q2 Earnings - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
Wedbush Research Analysts Reduce Earnings Estimates for TCRX - Defense World
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $10.00 - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Position Trimmed by Renaissance Technologies LLC - Defense World
Brokers Offer Predictions for TCRX Q1 Earnings - Defense World
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
TScan Therapeutics (TCRX) Price Target Lowered by HC Wainwright | TCRX Stock News - GuruFocus
What Analysts Are Saying About TScan Therapeutics Stock - Benzinga
TScan Therapeutics Reports Q1 2025 Financial Results - TipRanks
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics (TCRX) Exceeds Q1 Revenue Expectations | TCRX Stock News - GuruFocus
TScan Therapeutics Reveals Solid Progress: Key Clinical Data Coming in 2025, $251M War Chest Secured - Stock Titan
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Target Price from Brokerages - Defense World
JPMorgan Chase & Co. Acquires 34,951 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus
Geode Capital Management LLC Has $2.93 Million Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting - Nasdaq
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting - Yahoo
What is the investor’s view on Tscan Therapeutics Inc (TCRX)? - uspostnews.com
Investing in Tscan Therapeutics Inc (TCRX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages - Defense World
TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):